Rosalind Advisors, Inc.
13F Reported Value
ⓘ$379.1M
incl. option notional
Equity Holdings
ⓘ$266.2M
Option Notional
ⓘ$112.9M
$112.4M puts / $505,880 calls
Holdings
35
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Rosalind Advisors, Inc. disclosed 35 positions worth $379.1M in its Form 13F-HR for Q2 2026 — $266.2M in common stock plus $112.9M of put/call option positions (reported at underlying notional value, not premium at risk), followed by $DCTH and $FENC. During the quarter the fund opened 9 new positions and exited 12 and a full exit from $CGON. The portfolio is most concentrated in Healthcare (94.7% of disclosed assets). All figures are sourced directly from Rosalind Advisors, Inc.’s Form 13F-HR filing with the SEC under CIK 1622627.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
ISHARES TR - PUT PUT
—Quality
$110.0M500,000 sh- 54.7#1,308
Quality
$41.6M3,300,389 sh - 35.7#2,297
Quality
$34.3M3,188,001 sh - 56.5
Quality
$23.0M2,908,981 sh - —
Quality
$19.6M3,178,121 sh - 29.7
Quality
$15.2M3,986,509 sh - 28.0
Quality
$15.0M3,214,766 sh - 3.5
Quality
$14.1M988,230 sh - —
Quality
$12.9M1,956,814 sh - —
Quality
$11.9M648,600 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| ISHARES TR - PUT PUT | — | $110.0M | 500,000 |
 DELCATH SYSTEMS, INC.$DCTH | 54.7#1,308 | $41.6M | 3,300,389 |
 FENNEC PHARMACEUTICALS INC.$FENC | 35.7#2,297 | $34.3M | 3,188,001 |
 Xeris Biopharma Holdings, Inc.$XERS | 56.5 | $23.0M | 2,908,981 |
 Savara Inc$SVRA | — | $19.6M | 3,178,121 |
 Verastem, Inc.$VSTM | 29.7 | $15.2M | 3,986,509 |
 X4 Pharmaceuticals, Inc$XFOR | 28.0 | $15.0M | 3,214,766 |
 EyePoint, Inc.$EYPT | 3.5 | $14.1M | 988,230 |
 CYBIN INC.$HELP | — | $12.9M | 1,956,814 |
 Vor Biopharma Inc.$VOR | — | $11.9M | 648,600 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Rosalind Advisors, Inc.'s 35 positions.
Showing top 10 of 35 holdings.
Sector Allocation
Healthcare
$252.1M
Technology
$14.1M
Full Holdings — Rosalind Advisors, Inc. (Q2 2026)
All 35 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | — | ISHARES TR - PUT | $110.0M | — | NEW | — |
| 2 | $DCTH | DELCATH SYSTEMS, INC. | $41.6M | 15.6% | +0% | 54.7 |
| 3 | $FENC | FENNEC PHARMACEUTICALS INC. | $34.3M | 12.9% | +10% | 35.7 |
| 4 | $XERS | Xeris Biopharma Holdings, Inc. | $23.0M | 8.7% | -10% | 56.5 |
| 5 | $SVRA | Savara Inc | $19.6M | 7.3% | -1% | — |
| 6 | $VSTM | Verastem, Inc. | $15.2M | 5.7% | +86% | 29.7 |
| 7 | $XFOR | X4 Pharmaceuticals, Inc | $15.0M | 5.6% | +0% | 28 |
| 8 | $EYPT | EyePoint, Inc. | $14.1M | 5.3% | -5% | 3.5 |
| 9 | $HELP | CYBIN INC. | $12.9M | 4.9% | +28% | — |
| 10 | $VOR | Vor Biopharma Inc. | $11.9M | 4.5% | -7% | — |
| 11 |  $PCVX | Vaxcyte, Inc. | $11.6M | 4.4% | -31% | — |
| 12 |  $MDWD | MediWound Ltd. | $11.0M | 4.1% | +0% | — |
| 13 |  $CLDX | Celldex Therapeutics, Inc. | $7.4M | 2.8% | -39% | 8.4 |
| 14 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $7.2M | 2.7% | -22% | 53.2 |
| 15 |  $PROF | Profound Medical Corp. | $5.5M | 2.1% | +0% | — |
| 16 |  $TLPH | TALPHERA, INC. | $5.3M | 2.0% | +54% | — |
| 17 |  $AVIR | Atea Pharmaceuticals, Inc. | $5.0M | 1.9% | -9% | — |
| 18 |  $MYO | MYOMO, INC. | $3.8M | 1.4% | -5% | 30.2 |
| 19 |  $OVID | Ovid Therapeutics Inc. | $3.0M | 1.1% | +0% | 26.4 |
| 20 |  $NRXS | Neuraxis, INC | $3.0M | 1.1% | +78% | — |
| 21 |  $ABVX | Abivax S.A. | $2.8M | 1.0% | NEW | — |
| 22 |  $NSPR | InspireMD, Inc. | $2.7M | 1.0% | +0% | — |
| 23 |  $RGNT | REGENTIS BIOMATERIALS LTD. | $2.5M | 0.9% | +179% | — |
| 24 | — | SELLAS LIFE SCIENCES GROUP INC - PUT | $2.3M | — | NEW | — |
| 25 |  $PYPD | PolyPid Ltd. | $2.0M | 0.7% | -35% | — |
| 26 |  $BFRI | Biofrontera Inc. | $1.2M | 0.5% | +10% | 30.9 |
| 27 |  $KURA | Kura Oncology, Inc. | $1.1M | 0.4% | +0% | 27.6 |
| 28 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $1.1M | 0.4% | NEW | — |
| 29 |  $AQST | Aquestive Therapeutics, Inc. | $1.0M | 0.4% | +0% | 14.5 |
| 30 |  $OKUR | OnKure Therapeutics, Inc. | $684,000 | 0.3% | -66% | — |
| 31 |  $PEPG | PepGen Inc. | $630,000 | 0.2% | NEW | — |
| 32 |  $CGONCALL | CG Oncology, Inc. | $375,100 | — | NEW | 27 |
| 33 | $EYPTCALL | EyePoint, Inc. | $130,780 | — | NEW | 3.5 |
| 34 | — | SPDR SERIES TRUST - PUT | $35,150 | — | NEW | — |
| 35 |  $TENXPUT | TENAX THERAPEUTICS, INC. | $13,950 | — | NEW | — |
New Positions (9)
Exited Positions (12)
$CGON CG Oncology, Inc.
$VRDN Viridian Therapeutics, Inc.\DE
$REPLCALL Replimune Group, Inc.
$DFTX Definium Therapeutics, Inc.
$LPCN Lipocine Inc.
$AVTX Avalo Therapeutics, Inc.
$ANNX Annexon, Inc.
$QQQPUT INVESCO QQQ TRUST, SERIES 1
$SPYPUT SPDR S&P 500 ETF TRUST$VRDNPUT Viridian Therapeutics, Inc.\DE
$AVBPCALL ArriVent BioPharma, Inc.
$QURECALL uniQure N.V.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Rosalind Advisors, Inc. including:
Track Rosalind Advisors, Inc.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Rosalind Advisors, Inc. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Rosalind Advisors, Inc.
13F Pro is an AI hedge fund tracker and stock research platform. For Rosalind Advisors, Inc. (SEC CIK: 1622627), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Rosalind Advisors, Inc.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.